Exendin-4 promotes the membrane trafficking of the AMPA receptor GluR1 subunit and ADAM10 in the mouse neocortex

Regulatory Peptides

Volumn 190-191, Issue , 2014, Pages 1-11

  Ohtake, Nobuaki ^a   Saito, Mieko ^a   Eto, Masaaki ^a   Seki, Kenjiro ^a  

^a OHU UNIVERSITY   (Japan)

Author keywords

ADAM10; AMPA receptor GluR1 subunit; Exendin 4; Glucagon like peptide 1; Mouse neocortex

Indexed keywords

ADAM10 ENDOPEPTIDASE; ALPHA SECRETASE; AMPA RECEPTOR GLUR1 SUBUNIT; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; MAMMALIAN TARGET OF RAPAMYCIN; MEMBRANE PROTEIN; OLIGOMER; POSTSYNAPTIC DENSITY PROTEIN 95; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ADAM PROTEIN; ADAM10 PROTEIN, MOUSE; AMPA RECEPTOR; GLUTAMATE RECEPTOR IONOTROPIC, AMPA 1; PEPTIDE; SECRETASE; VENOM;

ADULT; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; ENZYME ACTIVITY; GENETIC TRANSCRIPTION; IN VIVO STUDY; LEARNING; LONG TERM POTENTIATION; MALE; MEMORY; MOUSE; NEOCORTEX; NERVE CELL PLASTICITY; NEUROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; SYNAPTIC MEMBRANE; UPREGULATION; ANIMAL; CELL MEMBRANE; CYTOLOGY; DRUG EFFECTS; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; METABOLISM;

ADAM PROTEINS; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CELL MEMBRANE; INFUSIONS, INTRAVENTRICULAR; MALE; MEMBRANE PROTEINS; MICE; NEOCORTEX; PEPTIDES; RECEPTORS, AMPA; VENOMS;

EID: 84900333085     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2014.04.003     Document Type: Article

References (55)

1. Ashe K.H. Learning and memory in transgenic mice modeling Alzheimer's disease. Learn Mem 2001, 8:301-308.
2. Masliah E., Miller A., Terry R.D. The synaptic organization of the neocortex in Alzheimer's disease. Med Hypotheses 1993, 41:334-340.
3. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991, 30:572-580.
4. Chan S.L., Furukawa K., Mattson M.P. Presenilins and APP in neuritic and synaptic plasticity: Implications for the pathogenesis of Alzheimer's disease. Neuromolecular Med 2002, 2:167-196.
5. Masliah E. Mechanisms of synaptic dysfunction in Alzheimer's disease. Histol Histopathol 1995, 10:509-519.
6. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 2002, 298:789-791.
7. Chapman P.F., White G.L., Jones M.W., Cooper-Blacketer D., Marshall V.J., Irizarry M., Younkin L., Good M.A., Bliss T.V., Hyman B.T., Younkin S.G., Hsiao K.K. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci 1999, 2:271-276.
8. Perry T., Lahiri D.K., Sambamurti K., Chen D., Mattson M.P., Egan J.M., Greig N.H. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res 2003, 72:603-612.
9. Han W.N., Holscher C., Yuan L., Yang W., Wang X.H., Wu M.N., Qi J.S. Liraglutide protects against amyloid-beta protein-induced impairment of spatial learning and memory in rats. Neurobiol Aging 2013, 34:576-588.
10. McClean P.L., Parthsarathy V., Faivre E., Holscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci 2011, 31:6587-6594.
11. Gault V.A., Holscher C. GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. Eur J Pharmacol 2008, 587:112-117.
12. During M.J., Cao L., Zuzga D.S., Francis J.S., Fitzsimons H.L., Jiao X., Bland R.J., Klugmann M., Banks W.A., Drucker D.J., Haile C.N. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003, 9:1173-1179.
13. Abbas T., Faivre E., Holscher C. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease. Behav Brain Res 2009, 205:265-271.
14. McIntyre R.S., Powell A.M., Kaidanovich-Beilin O., Soczynska J.K., Alsuwaidan M., Woldeyohannes H.O., Kim A.S., Gallaugher L.A. The neuroprotective effects of GLP-1: Possible treatments for cognitive deficits in individuals with mood disorders. Behav Brain Res 2013, 237:164-171.
15. Huang S., Trevino M., He K., Ardiles A., Pasquale R., Guo Y., Palacios A., Huganir R., Kirkwood A. Pull-push neuromodulation of LTP and LTD enables bidirectional experience-induced synaptic scaling in visual cortex. Neuron 2012, 73:497-510.
16. Collins-Hicok J., Lin L., Spiro C., Laybourn P.J., Tschumper R., Rapacz B., McMurray C.T. Induction of the rat prodynorphin gene through Gs-coupled receptors may involve phosphorylation-dependent derepression and activation. Mol Cell Biol 1994, 14:2837-2848.
17. Jhala U.S., Canettieri G., Screaton R.A., Kulkarni R.N., Krajewski S., Reed J., Walker J., Lin X., White M., Montminy M. cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2. Genes Dev 2003, 17:1575-1580.
18. Suzuki A., Fukushima H., Mukawa T., Toyoda H., Wu L.J., Zhao M.G., Xu H., Shang Y., Endoh K., Iwamoto T., Mamiya N., Okano E., Hasegawa S., Mercaldo V., Zhang Y., Maeda R., Ohta M., Josselyn S.A., Zhuo M., Kida S. Upregulation of CREB-mediated transcription enhances both short- and long-term memory. J Neurosci 2011, 31:8786-8802.
19. Bonkale W.L., Fastbom J., Wiehager B., Ravid R., Winblad B., Cowburn R.F. Impaired G-protein-stimulated adenylyl cyclase activity in Alzheimer's disease brain is not accompanied by reduced cyclic-AMP-dependent protein kinase A activity. Brain Res 1996, 737:155-161.
20. O'Neill C., Wiehager B., Fowler C.J., Ravid R., Winblad B., Cowburn R.F. Regionally selective alterations in G protein subunit levels in the Alzheimer's disease brain. Brain Res 1994, 636:193-201.
21. Robert S.J., Zugaza J.L., Fischmeister R., Gardier A.M., Lezoualc'h F. The human serotonin 5-HT4 receptor regulates secretion of non-amyloidogenic precursor protein. J Biol Chem 2001, 276:44881-44888.
22. Kastin A.J., Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 2003, 27:313-318.
23. Dovey H.F., John V., Anderson J.P., Chen L.Z., de Saint Andrieu P., Fang L.Y., Freedman S.B., Folmer B., Goldbach E., Holsztynska E.J., Hu K.L., Johnson-Wood K.L., Kennedy S.L., Kholodenko D., Knops J.E., Latimer L.H., Lee M., Liao Z., Lieberburg I.M., Motter R.N., et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 2001, 76:173-181.
24. Zheng Z., Sabirzhanov B., Keifer J. Oligomeric amyloid-{beta} inhibits the proteolytic conversion of brain-derived neurotrophic factor (BDNF), AMPA receptor trafficking, and classical conditioning. J Biol Chem 2010, 285:34708-34717.
25. Guo D., Zeng L., Brody D.L., Wong M. Rapamycin attenuates the development of posttraumatic epilepsy in a mouse model of traumatic brain injury. PLoS One 2013, 8:e64078.
26. Sakamoto K., Karelina K., Obrietan K. CREB: A multifaceted regulator of neuronal plasticity and protection. J Neurochem 2011, 116:1-9.
27. Agarwala S.S., Kirkwood J.M. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 2000, 5(2):144-151.
28. Cochet M., Donneger R., Cassier E., Gaven F., Lichtenthaler S.F., Marin P., Bockaert J., Dumuis A., Claeysen S. 5-HT4 receptors constitutively promote the non-amyloidogenic pathway of APP cleavage and interact with ADAM10. ACS Chem Neurosci 2013, 4:130-140.
29. Postina R. Activation of alpha-secretase cleavage. J Neurochem 2012, 120(Suppl. 1):46-54.
30. Li Y., Duffy K.B., Ottinger M.A., Ray B., Bailey J.A., Holloway H.W., Tweedie D., Perry T., Mattson M.P., Kapogiannis D., Sambamurti K., Lahiri D.K., Greig N.H. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis 2010, 19:1205-1219.
31. Jourdi H., Kabbaj M. Acute BDNF treatment upregulates GluR1-SAP97 and GluR2-GRIP1 interactions: Implications for sustained AMPA receptor expression. PLoS One 2013, 8:e57124.
32. Marcello E., Epis R., Saraceno C., Gardoni F., Borroni B., Cattabeni F., Padovani A., Di Luca M. SAP97-mediated local trafficking is altered in Alzheimer disease patients' hippocampus. Neurobiol Aging 2012, 33:422 e1-10.
33. Slipczuk L., Bekinschtein P., Katche C., Cammarota M., Izquierdo I., Medina J.H. BDNF activates mTOR to regulate GluR1 expression required for memory formation. PLoS One 2009, 4:e6007.
34. Li W., Keifer J. Coordinate action of pre- and postsynaptic brain-derived neurotrophic factor is required for AMPAR trafficking and acquisition of in vitro classical conditioning. Neuroscience 2008, 155:686-697.
35. Snyder E.M., Nong Y., Almeida C.G., Paul S., Moran T., Choi E.Y., Nairn A.C., Salter M.W., Lombroso P.J., Gouras G.K., Greengard P. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 2005, 8:1051-1058.
36. Skoglund G., Hussain M.A., Holz G.G. Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element. Diabetes 2000, 49:1156-1164.
37. Thathiah A., De Strooper B. The role of G protein-coupled receptors in the pathology of Alzheimer's disease. Nat Rev Neurosci 2011, 12(2):73-87.
38. Marcello E., Gardoni F., Mauceri D., Romorini S., Jeromin A., Epis R., Borroni B., Cattabeni F., Sala C., Padovani A., Di Luca M. Synapse-associated protein-97 mediates alpha-secretase ADAM10 trafficking and promotes its activity. J Neurosci 2007, 27:1682-1691.
39. Gerhart-Hines Z., Dominy J.E., Blattler S.M., Jedrychowski M.P., Banks A.S., Lim J.H., Chim H., Gygi S.P., Puigserver P. The cAMP/PKA pathway rapidly activates SIRT1 to promote fatty acid oxidation independently of changes in NAD(+). Mol Cell 2011, 44:851-863.
40. Donmez G., Wang D., Cohen D.E., Guarente L. SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. Cell 2010, 142:320-332.
41. Kim D., Nguyen M.D., Dobbin M.M., Fischer A., Sananbenesi F., Rodgers J.T., Delalle I., Baur J.A., Sui G., Armour S.M., Puigserver P., Sinclair D.A., Tsai L.H. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J 2007, 26:3169-3179.
42. Lee J., Hong S.W., Chae S.W., Kim D.H., Choi J.H., Bae J.C., Park S.E., Rhee E.J., Park C.Y., Oh K.W., Park S.W., Kim S.W., Lee W.Y. Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice. PLoS One 2012, 7:e31394.
43. Devi L. 7,8-Dihydroxyflavone, a small-molecule TrkB agonist, reverses memory deficits and BACE1 elevation in a mouse model of Alzheimer's disease. Neuropsychopharmacology 2012, 37:11.
44. Hu X. BDNF-induced increase of PSD-95 in dendritic spines requires dynamic microtubule invasions. J Neurosci 2011, 31:7.
45. Savonenko A.V. Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc Natl Acad Sci U S A 2008, 105:6.
46. Tan J.L., Li Q.X., Ciccotosto G.D., Crouch P.J., Culvenor J.G., White A.R., Evin G. Mild oxidative stress induces redistribution of BACE1 in non-apoptotic conditions and promotes the amyloidogenic processing of Alzheimer's disease amyloid precursor protein. PLoS One 2013, 8:e61246.
47. Rutten B.P., Wirths O., Van de Berg W.D., Lichtenthaler S.F., Vehoff J., Steinbusch H.W., Korr H., Beyreuther K., Multhaup G., Bayer T.A., Schmitz C. No alterations of hippocampal neuronal number and synaptic bouton number in a transgenic mouse model expressing the beta-cleaved C-terminal APP fragment. Neurobiol Dis 2003, 12:110-120.
48. Tamayev R., Matsuda S., Arancio O., D'Adamio L. Beta- but not gamma-secretase proteolysis of APP causes synaptic and memory deficits in a mouse model of dementia. EMBO Mol Med 2012, 4:171-179.
49. Wang H., Megill A., Wong P.C., Kirkwood A., Lee H.K. Postsynaptic target specific synaptic dysfunctions in the CA3 area of BACE1 knockout mice. PLoS One 2014, 9:e92279.
50. Laird F.M., Cai H., Savonenko A.V., Farah M.H., He K., Melnikova T., Wen H., Chiang H.C., Xu G., Koliatsos V.E., Borchelt D.R., Price D.L., Lee H.K., Wong P.C. BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci 2005, 25:11693-11709.
51. Holscher C. Diabetes as a risk factor for Alzheimer's disease: Insulin signalling impairment in the brain as an alternative model of Alzheimer's disease. Biochem Soc Trans 2011, 39:891-897.
52. Lee C.H., Yoo K.Y., Ryu P.D., Park J.H., Choi J.H., Kim S., Hwang I.K., Kim Y.M., Won M.H. õDecreased glucagon-like peptide-1 receptor immunoreactivity in the dentate granule cell layer from adult in the gerbil hippocampus. Cell Mol Neurobiol 2011, 31:345-350.
53. Ji W., Ha I. Drug development for Alzheimer's disease: Recent progress. Exp Neurobiol 2010, 19:120-131.
54. De Strooper B., Vassar R., Golde T. The secretases: Enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol 2010, 6:99-107.
55. Bomfim T.R., Forny-Germano L., Sathler L.B., Brito-Moreira J., Houzel J.C., Decker H., Silverman M.A., Kazi H., Melo H.M., McClean P.L., Holscher C., Arnold S.E., Talbot K., Klein W.L., Munoz D.P., Ferreira S.T., De Felice F.G. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Abeta oligomers. J Clin Invest 2012, 122:1339-1353.